The question facing cardiologists and patients now isn’t whether alternatives exist—it’s which one makes sense for your specific situation, your wallet, and your long-term cardiovascular risk.
Why Statins Still Remain the Foundation
Before exploring what comes next, it’s worth understanding why statins remain the first-line therapy for most patients. First approved in the late 1980s, statins do more than lower LDL cholesterol—they reduce heart attacks and death from heart disease, the nation’s leading killer. That track record spans decades. The drugs are metabolically efficient, generally well-tolerated, and the generic versions cost pennies compared to newer alternatives.
For the majority of patients, statins work. A typical dose brings LDL levels down to the recommended target of no more than 100 mg/dL—or no more than 70 mg/dL for people with existing cardiovascular disease or high risk. The math is simple: low cost, proven efficacy, minimal side effects for most people. Insurance companies love them. Patients appreciate not having to think about it.
But statins have hard limits.
The Statin Ceiling: Who Falls Through
Some patients hit a wall. Those with familial hypercholesterolemia—an inherited condition affecting about one in 250 people—can have LDL levels of 190 mg/dL or higher, even on maximum statin therapy. Their genetic makeup essentially overwhelms the drug’s ability to regulate cholesterol production.
Then there’s statin intolerance, the less visible but clinically significant problem. In controlled clinical trials, about 5% of patients report side effects severe enough to stop taking statins—typically muscle pain or weakness. But in real-world practice, that number climbs to 15%. The gap between trial data and everyday experience matters enormously when you’re the patient experiencing muscle aches that interfere with your quality of life.
For these populations, the old playbook offered limited options: ezetimibe (Zetia), which lowers LDL by about 20%, or PCSK9 inhibitors like alirocumab (Praluent) and evolocumab (Repatha). Both are proven to reduce heart attack risk. Both also carry significant cost barriers. PCSK9 inhibitors can run $10,000 to $15,000 per year, even with insurance, making them accessible primarily to patients with robust coverage or high-risk profiles that justify the expense.
The field needed something in between: more potent than ezetimibe, more affordable than PCSK9 inhibitors, and ideally with a different mechanism of action to avoid statin-related side effects.
The New Arrivals: Bempedoic Acid and Inclisiran
In the past two years, the FDA approved two drugs that reshape the treatment hierarchy: bempedoic acid (Nexletol) and inclisiran (Leqvio). Neither is a statin. Both work upstream in the cholesterol production pathway, but through different mechanisms entirely.
Bempedoic Acid: The Oral Alternative
Bempedoic acid arrives as a pill—a practical advantage for patients fatigued by injections or complex medication schedules. Taken alone, it lowers LDL by about 25%, a modest but meaningful reduction. The mechanism is clever: it interferes in the same cholesterol synthesis pathway as statins, but it only activates in the liver, theoretically sparing muscle tissue from the side effects that plague some statin users.
The real power emerges when bempedoic acid is combined with ezetimibe. This pairing, sold as Nexlizet, can cut LDL by about 40%—comparable to moderate-dose statins but achieved through a completely different route. For patients with documented statin intolerance, this opens a meaningful therapeutic option.
Cost matters here. Nexlizet is substantially cheaper than PCSK9 inhibitors, making it more likely to clear insurance approval hurdles. That affordability translates to actual access for patients who might otherwise be denied coverage or face prohibitive out-of-pocket costs.
The caveat: we don’t yet know if bempedoic acid prevents heart attacks or strokes. It lowers LDL, yes. But the clinical endpoint—does it actually save lives?—remains unproven. As Dr. Jorge Plutzky, director of preventive cardiology at Harvard-affiliated Brigham and Women’s Hospital, notes, this gap between surrogate markers and hard outcomes defines the current uncertainty around these newer agents.
Inclisiran: The Genetic Approach
Inclisiran takes a fundamentally different approach. Instead of blocking cholesterol production directly, it interferes with PCSK9’s genetic blueprint, preventing the protein from being made in the first place. The result: LDL levels drop by about 50%, rivaling or exceeding what most patients achieve with statins.
The convenience factor is striking. Inclisiran requires just two injections per year—a dramatic departure from daily pills or frequent infusions. For patients with familial hypercholesterolemia or severe statin intolerance, this represents a genuine advance in treatment burden.
But inclisiran carries the same evidentiary limitation as bempedoic acid: cardiovascular outcome data are limited. We know it slashes LDL. We don’t yet know if it prevents the heart attacks and strokes that patients actually fear.
The Evidence Gap: What You Need to Know Before Choosing
This distinction matters profoundly for anyone making a treatment decision. Statins have 30+ years of outcome data proving they reduce mortality. PCSK9 inhibitors have demonstrated cardiovascular benefit in major trials. The newer drugs—bempedoic acid and inclisiran—have robust LDL-lowering data but lack long-term outcome evidence.
For a patient with existing heart disease or very high cardiovascular risk, that gap is meaningful. Do you switch to a drug that lowers cholesterol beautifully but hasn’t yet proven it saves lives? Or do you stick with a statin, even if you don’t tolerate it well?
The answer depends on your individual risk profile, your tolerance for the statin side effects you’re experiencing, and your willingness to be an early adopter of a therapy with proven efficacy on a biomarker but unproven efficacy on clinical outcomes.
Choosing the Right Alternative: A Practical Framework
For patients unable to tolerate statins, the decision tree is clearer:
- Mild intolerance, LDL moderately elevated: Start with ezetimibe alone or Nexlizet (bempedoic acid + ezetimibe). Cost is reasonable. The 40% LDL reduction often achieves target levels.
- Severe intolerance, very high LDL or familial hypercholesterolemia: Inclisiran or a PCSK9 inhibitor. Inclisiran offers convenience and potency. PCSK9 inhibitors have outcome data. Both are expensive; insurance approval depends on clinical need.
- Statin-intolerant with established cardiovascular disease: The calculus shifts. You need proven mortality benefit. PCSK9 inhibitors remain the safest bet despite cost. Inclisiran and bempedoic acid may eventually prove equivalent, but the evidence isn’t there yet.
For patients who tolerate statins but don’t reach LDL targets, adding ezetimibe or bempedoic acid to a statin regimen often works before jumping to PCSK9 inhibitors. Sequential therapy is cheaper and more evidence-based than switching entirely.
The Cost Reality
Generic statins cost $11 per year. Ezetimibe adds roughly $30–50 annually. Nexlizet runs $200–400 per month without insurance. PCSK9 inhibitors cost $10,000–15,000 per year. Inclisiran’s pricing hasn’t yet stabilized in the market, but early projections suggest it will be significantly less than PCSK9 inhibitors, though more than Nexlizet.
Insurance approval hinges on documented statin intolerance or inadequate LDL lowering on maximum therapy. If you’re considering any of these alternatives, get your documentation in order. Prior authorization denials are common, and they delay treatment while you navigate appeals.
The Bottom Line for Your Decision
Statins remain the foundation of LDL management because they work, they’re affordable, and they save lives. The new alternatives aren’t replacements—they’re solutions for the patients statins fail. Bempedoic acid and inclisiran expand the toolkit, but they’re not yet proven to prevent cardiovascular events. If you tolerate statins, stay on them. If you don’t, or if you can’t reach target LDL despite maximum doses, these new options offer real hope. Just know what you’re gaining (convenience, tolerability, LDL reduction) and what you’re not yet gaining (long-term outcome data). Your cardiologist should help you weigh that tradeoff based on your individual risk and your values.